Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
ABILIFY MYCITE KIT is an oral aripiprazole tablet approved in 2017, an atypical antipsychotic with a multimodal mechanism involving partial agonism at dopamine D2 and serotonin 5-HT1A receptors and antagonism at 5-HT2A receptors. It is indicated for schizophrenia, bipolar disorder, schizoaffective disorder, major depressive disorder, and autism spectrum disorder. The digital formulation enables adherence monitoring through embedded ingestible sensors.
Product is at peak commercial maturity with moderate competitive pressure (30%), supporting stable team sizes across brand management, field sales, and medical affairs.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on ABILIFY MYCITE offers exposure to commercializing a differentiated digital health product within a mature therapeutic class, emphasizing market positioning, payer strategy, and adherence outcomes rather than novel mechanism discovery. Professionals should expect to develop expertise in competitive market navigation, health economics, and digital biomarker validation—valuable skills in the evolving mental health technology landscape.
Worked on ABILIFY MYCITE KIT at Otsuka? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/mo